RxDoctor Payments Data

Frederick Lewis, MD

Gastroenterology · Englewood, CONPI 1184738320

Payments from drug & device makers

$1,751in general payments, 2019–2025

Across 39 payments — averaging $44.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$862
  • Boston Scientific$331
  • Olympus America Inc.$185
  • Takeda Pharmaceuticals U.S.A., Inc.$140
  • Bristol Myers Squibb$84
  • Conmed Corporation$38
  • plus $111 from 4 others

What the payments were for

  • Food & beverage$1,73499%
  • Education$171%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,751 in reported general payments places this provider in the 45th percentile of 304 gastroenterology providers in Colorado.

See all gastroenterology providers in Colorado

Medicare billing

Part B allowed, 2024
$65,805
Medicare patients
255
Services billed
674

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab14$351,396
Humira(Cf) PenAdalimumab12$96,542
CreonLipase/Protease/Amylase24$61,446
SutabSod Sulf/Pot Chloride/Mag Sulf92$15,038
MotegrityPrucalopride Succinate15$14,218
LinzessLinaclotide11$13,638
Omeprazole428$8,615
Dexlansoprazole DrDexlansoprazole13$6,159
Sucralfate32$5,381
Budesonide DrBudesonide43$5,182
MovantikNaloxegol Oxalate24$4,906
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag24$3,012
Famotidine78$1,886
Esomeprazole Magnesium23$1,499
Pantoprazole Sodium64$733

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$15$351,39614 claims
AbbVieCreon, Linzess$862$75,08435 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$140$14,21815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 304 gastroenterology providers in Colorado.

Other gastroenterology in Englewood

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →